Clinical Trials Browser

Heterotaxy Syndrome × Vemurafenib × Head & Neck × Clear all

NCT02145143 2025-06-18

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Phase EARLY_PHASE1 Completed

Thyroid Neoplasms, Heterotaxy Syndrome